Sourced, dated developments across the GLP-1 and incretin class — Phase 3 trial readouts, FDA policy, new approvals, and guideline updates. Every item links to its primary source. We summarize; we don't reproduce.
Compounding alert. On 30 April 2026 the FDA proposed not adding semaglutide, tirzepatide, and liraglutide to the 503B bulks list, with public comments open through 29 June 2026. This could reshape access to compounded GLP-1s. Read our full breakdown or the primary notice at FDA.gov.
Eli Lilly's investigational triple agonist (GIP + GLP-1 + glucagon) reported topline TRIUMPH-1 results on 21 June 2026. Adults without diabetes on the 12 mg dose lost an average of 28.3% of body weight at 80 weeks; a higher-BMI extension subgroup reached roughly 30.3% at 104 weeks. Retatrutide remains investigational and is not FDA-approved.
A pre-specified blinded extension in participants with baseline BMI ≥35 who tolerated their dose reached an average ~30.3% body-weight reduction at 104 weeks on the 12 mg pathway.
In adults with obesity and knee osteoarthritis, 12 mg retatrutide produced an average ~28.7% weight loss at 68 weeks alongside reductions in OA pain — the program's first Phase 3 readout.
Lilly expects additional Phase 3 data in 2026 — TRIUMPH-2 (obesity with type 2 diabetes) and TRIUMPH-3 (obesity with established cardiovascular disease) — with a regulatory submission anticipated as the package matures.
Phase 3 programs are evaluating tirzepatide in inflammatory and autoimmune conditions — with ixekizumab in plaque psoriasis/psoriatic arthritis, and with mirikizumab in ulcerative colitis and Crohn's disease.
Both agents are in development as adjuncts in type 1 diabetes (largely mono- or combination-therapy designs), with completion dates extending across the rest of the decade.
Lilly's small-molecule oral GLP-1 orforglipron (referenced under the brand Foundayo) continues to progress, pointing toward pill-based options alongside injectables.
The FDA said it found insufficient evidence to add semaglutide, tirzepatide, and liraglutide to the 503B bulks list and opened a comment docket through 29 June 2026 before a final determination.
Coverage of the proposal notes the agency would remove bulks- and shortage-list pathways for these drugs, citing hundreds of adverse-event reports tied to compounded products — including dosing errors from multidose vials.
Compounded GLP-1s expanded during 2022 shortages at roughly $150–$300/month versus $1,000+ branded pricing; once the FDA declared shortages resolved, wind-down enforcement deadlines began reshaping the market.
Oral semaglutide became the first oral GLP-1 approved for chronic weight management, paired with secondary cardiovascular risk reduction — a meaningful step toward pill-based obesity care.
Novo Nordisk's higher-dose Wegovy injection was approved, positioned to deliver the largest weight loss to date within the Wegovy injectable line.
Injectable semaglutide received accelerated approval for metabolic dysfunction–associated steatohepatitis (MASH), extending GLP-1 benefit into liver disease.
Tirzepatide (Zepbound) became the first medication approved for moderate-to-severe obstructive sleep apnea in adults with obesity, used with a reduced-calorie diet and activity.
Injectable semaglutide (Ozempic) became the first GLP-1 approved to slow worsening chronic kidney disease and reduce cardiovascular death in adults with type 2 diabetes and CKD.
A direct comparison in obesity found tirzepatide produced greater average weight loss than semaglutide — one of the first head-to-head trials informing how the two are positioned.
The SELECT trial showed semaglutide reduced major cardiovascular events in people with overweight or obesity and established cardiovascular disease — a foundation for CV-risk labeling.
Presented at ECO 2026 and published in Nature Medicine, the update separates MASH resolution from liver-fibrosis improvement and clarifies distinct roles for tirzepatide and semaglutide using head-to-head evidence.
Obesity and dietitian societies issued an ECO 2026 consensus calling for incretin-based therapies to be integrated with dietetic, psychological, and functional support rather than used as standalone treatments.
Industry pipeline trackers flagged several GLP-1 regulatory decisions expected across early-to-mid 2026, reflecting how quickly the class is expanding into new indications and formulations.
Across recent labels, GLP-1 and GIP/GLP-1 agents now carry indications spanning cardiovascular risk, chronic kidney disease, obstructive sleep apnea, and MASH — not weight alone.
The FDA's April 2026 proposal is still in its comment period and is not a final rule. But it signals a tighter future for large-scale compounded semaglutide and tirzepatide. Patients relying on compounded GLP-1s — including those using cash-pay telehealth platforms such as NexLife — need to follow the docket and discuss contingency options (branded therapy, eligibility, or alternative dosing) with a licensed clinician.
Compounded semaglutide and tirzepatide are not FDA-approved finished drug products and are not the different from Ozempic®, Wegovy®, and Rybelsus®. Nothing here is medical advice.
This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.
| Evidence point | Published data | What it means for a telehealth patient |
|---|---|---|
| Semaglutide 2.4 mg, STEP 1 | Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo. | Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility. |
| Tirzepatide, SURMOUNT-1 | Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo. | Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing. |
| Compounded GLP-1 status | FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. | Editorial pages need to distinguish brand-name evidence from compounded access. |
| State access | Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping. | Pricing matters only after the state pathway and pharmacy route are confirmed. |
Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.